COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Yang, M. C. [1 ]
Tan, E. C. H. [1 ]
机构：
[1] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN19
引用
收藏
页码：A736 / A736
页数：1
相关论文
共 50 条
  • [41] Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
    Ahn, Hee Kyung
    Kim, Young Saing
    Kim, Eun Young
    Kyung, Sun Young
    Kang, Shin Myung
    Cho, Eun Kyung
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S910 - S911
  • [42] COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL
    Pinto, C. G.
    Manacas, M.
    Miguel, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A222 - A222
  • [43] Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer
    Parody-Rua, Elizabeth
    Augusto Guevara-Cuellar, Cesar
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 93 - 98
  • [44] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CARCINOMA IN PORTUGAL
    Pinheiro, B. A.
    Alarcao, J.
    Silva Miguel, L.
    Huang, M.
    Chandwani, S.
    Vargas Lopes, F.
    Borges, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A432 - A432
  • [45] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [46] Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach
    Hui, Wen
    Gao, Zhixiang
    Zhu, Min
    Wu, Huazhang
    Cai, Yuanyi
    [J]. BMC CANCER, 2024, 24 (01)
  • [47] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    [J]. ADVANCES IN THERAPY, 2021, 38 (07) : 3962 - 3972
  • [48] Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
    Lu, Shun
    Ye, Ming
    Ding, Lieming
    Tan, Fenlai
    Fu, Jie
    Wu, Bin
    [J]. ONCOTARGET, 2017, 8 (06) : 9996 - 10006
  • [49] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    [J]. PLOS ONE, 2018, 13 (10):
  • [50] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Qiao Liu
    Lidan Yi
    Xia Luo
    Sini Li
    Liting Wang
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    [J]. Advances in Therapy, 2021, 38 : 3962 - 3972
12345